FOURNEL ADVISORY advises ATHENA PHARMACEUTIQUES on the acquisition, alongside SUBSTIPHARM, of a shared controlling interest in VECTANS PHARMA
Athena develops and manufactures high value-added medicines for both mature and emerging markets. The company offers an integrated platform covering the full value chain—from R&D to commercialization—through its two manufacturing sites in France and India (with a third site planned for 2026) and its R&D centers.
This joint investment enables Athena Pharmaceutiques to partner with a differentiated technology player, integrate a portfolio of innovative products already marketed in over 75 countries, and strengthen its international footprint in high-value therapeutic segments.
Vectans is a French pharmaceutical company specialized in muco-adhesive treatments for oral and vaginal conditions. The company markets two innovative best-in-class drugs, distributed across 78 countries, and is developing a pipeline of more than 10 drug candidates formulated using its proprietary Lauriad® technology.